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Is thyroid stunning clinically 
relevant? A retrospective 
analysis of 208 patients
O atordoamento da tireoide é clinicamente relevante? 
Análise retrospectiva de 208 pacientes
Elba C. S. C. Etchebehere¹, Allan O. Santos¹, Patrícia S. Matos², Lígia V. M. 
Assumpção3, Maria Cecília V. L. Lima¹, Mariana C. L. Lima1, Laura S. Ward4
ABSTRACT
Objective: Current guidelines have advised against the performance of 131I-iodide diagnostic 
whole body scintigraphy (dxWBS) to minimize the occurrence of stunning, and to guarantee 
the efficiency of radioiodine therapy (RIT). The aim of the study was to evaluate the impact of 
stunning on the efficacy of RIT and disease outcome. Subjects and methods: This retrospective 
analysis included 208 patients with differentiated thyroid cancer managed according to a same 
protocol and followed up for 12-159 months (mean 30 ± 69 months). Patients received RIT in do-
ses ranging from 3,700 to 11,100 MBq (100 mCi to 300 mCi). Post-RIT-whole body scintigraphy 
images were performed 10 days after RIT in all patients. In addition, images were also perfor-
med 24-48 hours after therapy in 22 patients. Outcome was classified as no evidence of disease 
(NED), stable disease (SD) and progressive disease (PD). Results: Thyroid stunning occurred 
in 40 patients (19.2%), including 26 patients with NED and 14 patients with SD. A multivariate 
analysis showed no association between disease outcome and the occurrence of stunning (p 
= 0.3476). Conclusion: The efficacy of RIT and disease outcome do not seem to be related to 
thyroid stunning. Arq Bras Endocrinol Metab. 2014;58(3):292-300
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RESUMO
Objetivo: As diretrizes atuais alertam contra a execução da cintigrafia de corpo inteiro com 
iodo-131 (dxWBS) para minimizar a ocorrência de atordoamento e garantir a eficiência do tra-
tamento com radioiodo (RIT). O objetivo deste estudo foi avaliar o impacto do atordoamento 
sobre a eficácia do RIT e desfechos da doença. Sujeitos e métodos: Esta análise retrospectiva 
incluiu 208 pacientes com câncer diferenciado de tireoide submetidos ao mesmo protocolo e 
acompanhados por 12-159 semanas (média de 30 ± 69 meses). Os pacientes receberam RIT 
com doses variando de 3.700 a 11.100 MBq (100 mCi a 300 mCi). As imagens da cintigrafia 
após a RIT foram feitas 10 dias depois da RIT em todos os pacientes. Além disso, as imagens 
foram também obtidas após 24-48h em 22 pacientes. O desfecho foi classificado como nenhu-
ma evidência de doença (NED), doença estável (SD) e doença progressiva (PD). Resultados: O 
atordoamento da tireoide ocorreu em 40 pacientes (19,2%), incluindo 26 pacientes com NED e 
14 pacientes com SD. A análise multivariada não mostrou associação entre o desfecho da doen-
ça e a ocorrência de atordoamento (p = 0,3476). Conclusão: A eficácia da RIT e o desfecho da 
doença não parecem estar relacionados com o atordoamento da tireoide. Arq Bras Endocrinol Metab. 
2014;58(3):292-300
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INTRODUCTION
Differentiated thyroid cancer (DTC) may be treated 
by total thyroidectomy, 131I-iodide therapy (RIT), 
and hormone suppression therapy (1,2). Prior to RIT, 
whole-body diagnostic scintigraphy with 131I-iodide 
(dxWBS) may be performed for treatment planning. 
However, the performance of dxWBS, as well as the 
dose recommended for the procedure is controversial 
due to many descriptions regarding thyroid stunning. 
Thyroid stunning is defined as a reduction or absence 
of 131I-iodide uptake in the cervical region observed 
on post-therapy whole body scintigraphy performed 
after a diagnostic dose of 131I-iodide (post-RIT-WBS) 
(3). This phenomenon, as hypothesized, would impair 
the uptake of a subsequent RIT, leading to ineffec-
tive treatment (4). Therefore, some institutions have 
abandoned dxWBS, preferring to perform RIT with 
empirical doses to prevent the occurrence of thyroid 
stunning. Other institutions have substituted diagnos-
tic 131I-iodide-WBS for 123I-iodide-WBS, although the 
costs of the latter are higher, and the stunning effect, 
due to the emission of Auger electrons by 123I-iodide, 
could be more severe than with 131I-iodide (5). Howe-
ver, the true nature of this phenomenon remains uncer-
tain. Moreover, there is no clear evidence that stunning 
actually interferes with disease outcomes.
Conversely, dxWBS has many benefits, distinguish-
ing patients who may actually benefit from treatment 
from those who should not be treated (no cervical up-
take with low thyroglobulin levels; large surgical thy-
roid remnants; undetected distant metastases). The 
correct assessment of disease sites can be used to deter-
mine and program RIT without exposing the patient 
to the risk of ineffective empirical doses. If the Nuclear 
Medicine physician decides not to perform a dxWBS 
prior to RIT, he may have to assume legal responsibility 
for performing empirical treatment doses of iodine-131I 
in patients without cervical 131I-iodide uptake. 
This study aimed to retrospectively evaluate the 
clinical impact and efficacy of RIT in patients with 
DTC with and without stunning.
SUBJECTS AND METHODS
This retrospective study was approved by the Resear-
ch Ethics Committee of the School of Medical Scien-
ces of the Universidade Estadual de Campinas (CEP # 
1079/2009).
Patients
A total of 208 patients with differentiated thyroid car-
cinoma consecutively referred to our Nuclear Medicine 
facility for RIT from 1998 to 2012 were retrospectively 
reviewed. 
All patients were submitted to total thyroidectomy, 
with or without lymph node dissection, depending on 
neck ultrasound and intraoperative findings, and re-
ferred for RIT. Serum thyroglobulin (Tg) levels, anti-
thyroglobulin antibodies (TgAb), and TSH were ob-
tained before and after thyroid hormone withdrawal, 
immediately prior to a 131I-iodide dxWBS. All patients 
were followed up with regular serum Tg, TSH and 
TgAb measurements; annual cervical ultrasonography; 
annual dxWBS; and other eventual diagnostic imag-
ing modalities, such as computed tomography, 99mTc-
sestamibi whole body scintigraphy, 201-thallium whole 
body scintigraphy, 18F-FDG-PET/CT (after 2008), 
and bone scintigraphy for a period range of 12-159 
months (mean 30 ± 69 months). Patients with high or 
increasing serum Tg levels (> 2 mg/dL) and/or suspi-
cious whole body scans were submitted to a thorough 
imaging studies. 
Patients were classified according to pTNM stag-
ing for DTC (1,2). Urine iodine measurements are not 
routinely measured in our facility.
131I-Iodide DxWBS 
All patients were oriented to follow a low iodine diet 
for 15 days, refraining from iodide-rich substances, as 
well as intravenous iodide contrasts for three months 
prior to dxWBS. All patients received 185 MBq (5 
mCi) of 131I-iodide. Images were performed after 48 
hours using a dual-head scintillation camera, with high-
-energy parallel-hole collimators. The photopeak was 
centered at 364 KeV with 15% energy window level, 
and bed speed of 5 cm per minute.
RIT and post-RIT-WBS
In addition to the dxWBS, blood cell counts, serum 
TSH, Tg, TgAb levels and pregnancy tests were perfor-
med one week prior to RIT. All RIT were performed 
with TSH levels above 30 mUI/L, under hypothyroi-
dism after a 30 days suspension of thyroid hormone tre-
atment with levothyroxine. Doses administered ranged 
from 3,700 MBq to 11,100 MBq (100 to 300 mCi), as 
follows: 3,700 MBq or 100 mCi for cervical remnants 
only; 5,550 MBq or 150 mCi for lymph node metastasis; 
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7,400 MBq or 200 mCi for lung metastases, and 9,250 
- 11,100 MBq or 250 - 300 mCi for bone involvement. 
Post-therapeutic WBS (post-RIT-WBS) was per-
formed on all 208 patients 10 days after discharge, with 
the same parameters used on the dxWBS. 
A subgroup of 22 patients also underwent two post-
RIT-WBS: one after 24-48 hours and another after 10 
days. In this subgroup of patients, the bed speed of the 
24-48 hour post-RIT-WBS was 10 cm per minute due 
to higher radioactivity counts.
Classification of thyroid stunning 
Two experienced nuclear medicine physicians visually 
assessed images from the dxWBS and post-RIT-WBS. 
In case of discordant findings, a third nuclear medicine 
physician reviewed the study. The readers were blinded 
to other studies and clinical outcomes. They blindly 
classified the patients as: no stunning, partial stunning, 
or total stunning. The classification of stunning was 
performed only after the first radioiodine treatment, 
taking into consideration cervical uptake and eventual 
metastases. Subsequent treatments were not conside-
red for the occurrence of stunning. Uptake reduction 
in at least one of the foci was enough to classify the 
patient as having thyroid stunning.
Classification of stunning was performed as follows: 
1. No stunning: uptake in post-RIT-WBS was 
equal to uptake on the dxWBS. 
2. Partial stunning: uptake in 10 days post-RIT-
WBS was partially reduced when compared 
with dxWBS (Figure 1). 
3. Total stunning: uptake in 10 days post-RIT-
WBS was absent when compared with dxWBS 
(Figure 2).
Among the 22 patients who also underwent a post-
RIT-WBS 24-48 hours after discharge, there were six 
patients presenting a partial stunning with washout pat-
tern: the 24-48 hours uptake post-RIT-WBS was equal 
to the uptake seen on dxWBS. However, 10 days post-
RIT-WBS, the uptake was partially reduced, as demon-
strated in figure 3.
Disease status classification
Patients were classified as: no evidence of disease 
(NED); stable disease (SD); and progressive disease 
(PD). This classification was performed one year after 
each RIT and at the end of the follow-up period. Thus, 
for example, if a patient was submitted to three RIT, 
Figure 1. An example of a partial stunning. (A) 131I-iodide dxWBS shows 
increased cervical uptake. (B) Post-RIT-WBS shows a partial reduction of 
the cervical uptake when compared with (A).
Figure 2. An example of a total stunning. (A) 131I-iodide dxWBS shows 
increased cervical uptake. (B) Post-RIT-WBS shows a no cervical uptake 
when compared with (A).
Is thyroid stunning clinically relevant?
he was reclassified one year after each treatment and at 
the end of follow-up. This classification was based on 
the results of the annual dxWBS; the suppressed and 
stimulated serum Tg levels; the neck ultrasound and 
on other eventual imaging data (18F-FDG PET/CT or 
99mTc-sestamibi).
Patients were classified as NED when presenting all 
of the following conditions: negative annual dxWBS; 
negative annual cervical ultrasound; serum Tg levels 
below 1.0 ng/mL on levothyroxine and with stimu-
lated Tg levels, and negative TgAb. 
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Figure 3. An example of progressive washout in a young female patient. (A) 131I-iodide dxWBS depicts markedly increased cervical uptake. (B) 24 hours 
post-RIT-WBS shows basically the same cervical uptake when compared with 131I-iodide dxWBS. (C) 10 days post-RIT-WBS shows a marked reduction in 
the cervical uptake. 
The SD classification was based on one or more 
of the following conditions: persistent cervical uptake 
and/or metastases on the annual dxWBS or neck ul-
trasound; Tg non-stimulated levels above 1.0 ng/
mL, with stimulated Tg levels above 10.0 ng/mL (but 
without progressive elevation); positive stable levels of 
TgAb. 
Patients were classified as PD when presenting any 
of the following parameters: new metastases detected at 
annual dxWBS or neck ultrasound; new metastases de-
tected in other imaging modalities; progressive increase 
of serum Tg levels despite RIT.
Statistical analysis
The statistical analysis was carried out using the SAS 
System for Windows (Statistical Analysis System, ver-
sion 9.1.3, Service Pack 3. SAS Institute Inc., 2002-
2003, Cary, NC, USA). The Pearson’s chi-square 
test was performed to evaluate the association be-
tween the occurrence of stunning and gender, histo-
logical subtype, aggressive variants, the presence of 
metastases at diagnosis, Tg levels and disease status. 
Nonparametric analysis was performed using either 
the chi-square or Fisher’s exact tests as indicated. The 
Mann-Whitney was performed to compare the pre-
sence of stunning with cumulative doses of 131I-iodi-
de. A multiple logistic regression analysis was used to 
evaluate the role of the occurrence of stunning and 
the pTNM stage; the initial and final serum Tg and 
TgAb levels; tumor histology; and the presence of 
metastases at diagnosis. All tests were conducted with 
a 0.05 level of significance.
RESULTS
Patient population data
As expected, most DTC patients were female (85%), 
with a mean age of 43.3 ± 14.1 years, as represented in 
table 1. There were 178 (85.6%) papillary thyroid car-
cinomas including 46 (22.1%) cases of variants conside-
red aggressive (tall cell, columnar cell, diffuse sclerosing, 
solid/trabecular, and insular variants); and 30 (14.4%) 
follicular carcinomas (all of them widely invasive).
According to the pTNM staging, there were 105 
(50.5%) stage I patients; 43 (20.7%) stage II; 18 (8.7%) 
stage III; and 42 (20.2%) stage IV patients. Among the 
stage IV patients, 6 were IVa and 36 were IVb. Distant 
metastases at diagnosis occurred in 28 (13.5%) patients.
Only one patient did not present any cervical uptake 
in the dxWBS. However, RIT was performed because 
of high serum thyroglobulin (89.8 ng/mL) levels. 
The patient doses ranged from a single dose of 
3,700 MBq (100 mCi) in 55.8% of the cases to a maxi-
mum of four treatment doses that cumulated to 40,700 
MBq (1100 mCi) (Table 2). The entire patient popu-
lation was submitted to initial doses only for thyroid 
remnants and among these, 89% of the patients were 
submitted to only one dose. The remaining 11% were 
submitted to more doses because metastatic disease de-
veloped later on during follow-up. 
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Thyroid stunning
There was no inter-observer variability in any of the stu-
dies. Thyroid stunning occurred in 40 patients (19.2%) 
(Table 1). Thirty-four out of these patients (85%) were 
classified as partial stunning and 6 (15%) were classified 
as total stunning. There was a significant association be-
tween stunning and gender, which was more common 
in females, and may be related to sample size (p = 0.05; 
Pearson’s Chi-Square test). However, a significant in-
verse relationship between stunning and age was noted 
(Z = - 3.74; p < 0.000001; Mann-Whitney test). Youn-
ger patients tended to have more stunning effects than 
older patients. 
There was no association between stunning and the 
histological classification (p = 0.059; Pearson’s Chi-
Square test). However, we observed that nonaggres-
sive variants of papillary thyroid carcinomas presented 
Table 1. Comparison of clinical, pathological and outcome data between patients who showed stunning or not 
Mean ± SD
(min – max)
Total number of 
patients (percentage)
Non-stunning
(percentage)
Stunning
(percentage)
p-value
Patients  208 168 (80.8) 40 (19.2)
Initial Tg levels 136.8 ± 638.3
(0.2 to 6,000)
194 157 (80.9) 37 (19.1) Z-score = -1.422
P < 0.155***
Final Tg levels 185.0 ± 1053.4
(0.2 to 11,480)
207 168 (81.2) 39 (18.8) Z-score = -1.309
P < 0.191***
Cumulative RIT dose 263.8 ± 219.1
(92 to 1,100)
208 168 (80.8) 40 (19.2) Z-score = -2.239
P < 0.025***
Age 43.3 ± 14.1 208 168 (80.8) 40 (19.2) Z-score = -3.740
P < 0.0001***
Gender Female 177 (85.1) 139 (78.5) 38 (21.5) 0.05*
Male 31 (14.9) 29 (93.5) 2 (6.5)
Histology Follicular 30 (14.4) 28 (93.3) 2 (6.7) 0.059*
Papillary 178 (85.6) 140 (78.7) 38 (21.3)
PTC variant Aggressive 46 (22.1) 43 (93.5) 3 (6.5) 0.013*
Non-aggressive 162 (77.9) 125 (77.2) 37 (22.8)
Initial TgAb levels Negative 176 (84.6) 145 (82.4) 31 (17.6) 0.337**
Positive 18 (8.6) 13 (72.2) 5 (27.8)
Final TgAb levels Negative 195 (93.7) 158 (81.0) 37 (19.0) 0.718**
Positive 13 (6.3) 10 (76.9) 3 (23.1)
TNM I/II 148 (71.2) 108 (73.0) 40 (23.0) < 0.0001*
III/IV 60 (28.8) 60 (100) 0 (0)
Presence of metastases 
at diagnosis
No 179 (86.1) 142 (79.3) 37 (20.7) 0.215*
Yes 28 (13.4) 25 (89.3) 3 (10.7)
Clinical outcome NED 121 (58.2) 95 (78.5) 26 (23.5) 0.34****
SD 64 (30.8) 50 (78.1) 14 (21.9)
PD 23 (11.1) 23 (100) 0 (0)
* Pearson’s Chi-Square Test; ** Fisher’s Exact Test; *** Mann-Whitney U Test; **** Multiple Logistic Regression Analysis.
Table 2. Initial radioiodine therapy doses in the entire patient population, according to the presence and region of metastases 
Location of uptake MBq (mCi) Total number of patients (percentage)
Initial radioiodine therapy 
dose in MBq
Cervical uptake without lymph node metastases 3,700 (100) 116 (55.8)
Lymph node metastases 5,550 (150) 70 (33.7)
Lung metastases 7,400 – 9,250 (200 – 250) 21 (10.0)
Bone metastases > 9,250 (above 250) 1 (0.5)
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stunning more frequently then aggressive variants 
(p = 0.013; Pearson’s Chi-Square test). In addition, the 
phenomenon was more frequent in pTNM stages I and 
II than in stages III and IV patients (p < 0.001; Pear-
son’s Chi-Square test) (Table 1).
The initial serum Tg levels (before thyroid hormone 
withdrawal) were of 136.8 ± 638.3 (mean ± standard 
deviation) and ranged from 0.2 to 6000.0. There was 
no association between stunning and initial serum Tg 
levels (Z = - 1.422; p = 0.155; Mann-Whitney test).
Final serum Tg levels were of 185.0 ± 1053.4 (mean 
± standard deviation) and ranged from 0.2 to 11480.0. 
There was no association between stunning and final 
serum Tg levels (Z = - 1.309; p = 0.191; Mann-Whit-
ney test). 
No associations were noted between stunning and 
initial serum TgAb levels as well (p = 0.337; Fisher’s 
exact test); follow-up TgAb levels (p = 0.718; Fisher´s 
exact test); disease recurrence (p = 1.000; Fisher’s exact 
test); or the presence of metastases at diagnosis (p = 
0.215; Pearson’s chi-square test). 
The RIT cumulative doses were of 263.8 ± 219.1 
mCi and ranged from 92 to 1100 mCi. Stunning did 
not occur in patients who required more RITs (p = 
0.020; nonparametric Mann-Whitney test) or higher 
cumulative doses (p = 0.025; nonparametric Mann-
Whitney test). Thus, stunning did not occur in patients 
who were followed-up for a longer period of time due 
to PD (p = 0.002; nonparametric Mann-Whitney test) 
(Table 1).
Disease status data
One year after the first RIT, patients were classified 
according to the disease status, as follows: 127 NED 
patients (61.1%), 59 SD patients (28.4%), and 22 PD 
patients (10.5%). Six patients (2.9%) recurred (3 pa-
tients after two years of the first RIT and 3 patients 
after two years of the second RIT). Therefore, patients 
were reclassified as: NED – 121 patients (58.2%), SD 
– 64 patients (30.8%) and PD – 23 patients (11.1%).
In the NED group, 21.5% (26/121) of the patients 
presented stunning, while in the SD group, stunning 
occurred in 21.8% (14/64) of the cases. None of the 
PD patients presented stunning.
Multiple logistic regression analysis showed that the 
presence of stunning had no association with gender 
type nor with pTNM stages III and IV, the presence 
of metastasis or Tg levels. In addition, stunning occur-
rence had no impact on disease outcome (p = 0.33).
DISCUSSION
There is no agreement whether to perform diagnostic 
whole-body scintigraphy (dxWBS) prior to radioiodine 
therapy (RIT) or not in patients with well-differentia-
ted thyroid cancer. Numerous authors and organiza-
tions have argued either to perform dxWBS prior to 
RIT (6-8), or not to perform it (9,10) in these patients. 
Although this is a controversial issue in the literature, 
recent studies published by well-known journals and 
several world-wide renowned institutions still consider 
not only that dxWBS is an essential exam, but also an 
important tool to better understand the stunning phe-
nomenon. Chen and cols. (8) recommend dxWBs prior 
to RIT to provide the information required to prescri-
be an appropriate dose of 131I-iodide for effective treat-
ment, stating the importance of unsuspected lymph no-
des or distant metastases, which involve a significantly 
higher dose, besides the diagnosis of unexpected large 
thyroid remnants, in which a new surgery or a two-step 
ablation may be necessary.
Another study that supports the dxWBS prior to 
ablation was published by Van Nostrand and cols. (6). 
The authors support the performance of this exam, for 
it can be useful by demonstrating findings that may al-
ter the patient management prior to RIT in the fol-
lowing situations: absence of 131I-iodide uptake in the 
thyroid bed; a significant number of foci of uptake in 
the thyroid bed/neck region; multiple foci in the neck 
outside the thyroid bed; distant metastases and/or 
breast uptake.
The European consensus (9) also questions the use 
of dxWBS prior to ablation, stating that this exam may 
be avoided without loss of information. However, at 
the same time, the authors comment that dxWBS could 
be performed by some centers in some situations, for 
example when there is uncertainty concerning the ex-
tent of thyroidectomy, for large thyroid remnants that 
may require new surgery, or the use of corticosteroids 
to avoid radiation thyroiditis. According to the edito-
rial by McDougall (11), the European consensus ac-
knowledges that patient information regarding stage 
obtained after RIT is contrary to “good medicine” 
should be practiced, considering that all the diagnostic 
data should be obtained first and that the treatment 
should be based on that information.
We believe that not performing dxWBS prior to 
RIT reduces the quality of patient management. We 
frequently receive patients with very poor or no sur-
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gical description at all, many times with large thyroid 
remnants that may benefit from a second thyroidecto-
my before RIT. These large remnants may cause radia-
tion thyroiditis if treated blindly (12). Besides, dxWBS 
provides important information considering not only 
the amount of thyroid remnants, but also a complete 
evaluation and diagnosis of unsuspected lymph node 
metastases, which require a significantly higher dose of 
RIT (8). 
No cervical uptake (no remnants), on the other 
hand, may occur following total thyroidectomy. An ul-
trasound to detect the presence of absence of thyroid 
remnants has low sensitivity and does not substitute 
dxWBS for this purpose (8). Patients that are found 
to have no cervical uptake (no remnants) on a post-
therapy WBS most likely will not benefit from RIT. 
Therefore, if the Nuclear Medicine physician does not 
perform a dxWBS prior to RIT, it is the Nuclear Medi-
cine physician who may have to assume possible legal 
responsibility for performing empirical RIT in patients 
without cervical 131I-iodide uptake. 
Thus, as McDougall again states in his editorial 
(11), one of the essentials of treating patients with can-
cer is to know the extent of the disease as accurately 
as possible. The authors’ opinion considering the legal 
responsibility is exactly supported by this precaution, 
always searching for the best evaluation of each patient.
On the contrary, larger dosages of radioiodine may 
be administered at the time of ablation if regional or 
distant metastases are detected on a pre-ablation scan 
(8). In addition, the use of dxWBS prior to RIT may 
identify unsuspected uptake in the breast due to lacta-
tion or medication (13) and distant brain metastases 
(14). Patients with breast uptake should only be treated 
after the uptake is reduced to prevent mastitis. Brain 
metastases, albeit in a minority of patients, should be 
treated with corticosteroids or radiotherapy prior to 
RIT in order to prevent swelling (13,14).
However, most guidelines, including the ones by 
the American Thyroid Association and the National 
Comprehensive Cancer Network, advise against the 
performance of dxWBS in order to minimize the oc-
currence of stunning and guarantee the efficiency of 
RIT (1,2,15), even though they recognize that this 
phenomenon is not clearly understood and does not 
seem to have an impact on the patient outcome (16). 
Thyroid stunning is defined as a reduction or absence 
of 131I-iodide uptake in the cervical region observed on 
the post-RIT-WBS due to impairment of uptake of a 
subsequent RIT, leading to ineffective treatment. This 
phenomenon is not known to be due to post-diagnostic 
scan time dependent. In fact, a few studies concluded 
that thyroid stunning could cause a worse clinical out-
come, as it is associated with the need for more RIT 
sessions (4,17). On the contrary, other studies compar-
ing the efficacy of radioiodine therapy between patients 
submitted to dxWBS prior to RIT, and patients not 
submitted to pretreatment scan prior to RIT failed to 
show differences in success rates of RIT or in patient 
outcomes (18-20).
The current study, although retrospective, is com-
posed by a large cohort of patients submitted to the 
same management protocol and followed up for a 
considerable period of time (mean of 60 months). We 
clearly documented stunning in 40 (19.2%) patients. 
Nevertheless, no difference in outcomes occurred 
among them, and the rest of the 168 (80.8%) patients 
did not show stunning. It would be interesting to fol-
low up patients for a longer period of time, considering 
that recurrence of thyroid cancer can occur up to 10 
years after the initial treatment. 
Interestingly, in six out of the 22 patients who un-
derwent two post-RIT-WBS (after 24-48 hours and 
after ten days), a “partial stunning with washout” was 
observed. This pattern could represent faster thyroid 
turnover, since cervical uptake seen in the dxWBS was 
equal to that seen on the 24-48 hours post-RIT-WBS, 
and this uptake was reduced during the ten days post-
RIT-WBS in all these patients. Hence, thyroid stun-
ning may actually represent, in some patients, a partial 
treatment effect rather than a reduction in treatment 
efficacy. As the effective half-life of the iodine-131 can 
be shorter under TSH stimuli (< 3 days), it may be 
impossible to differentiate if the reduction of thyroid 
activity is due to physiologic washout of iodine from 
the thyroid gland, or because of the stunning effect. 
However, our cohort of 22 patients presented activity 
in the liver, what might strength the hypotheses of phys-
iologic clearance of iodine from the thyroid, as shown 
in figure 2. The same effect has also been observed by 
Sisson and cols., who demonstrated an early destructive 
effect of RIT when performing dxWBS after two days 
(21). Current imaging protocols and The Society of 
Nuclear Medicine and Molecular Imaging (SNMMI) 
guidelines recommend imaging of post-RIT-WBS four 
to ten days after administering RIT to enhance sensitiv-
ity (22). However, if the scans were to be performed in 
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the 24-48 hours following RIT, thyroid stunning could 
pass unnoticed in the majority of the patients. 
The weaknesses in our study include the fact that it 
is retrospective and, therefore, we could not compare 
the outcome of patients who did and did not receive 
dxWBS prior to treatment. Also, unfortunately, only a 
subset of patients (22) underwent a 24-48 hours post-
RIT-WBS, which we defined as “partial stunning with 
washout”. We do not know how many other subjects 
would have demonstrated this finding if 24-48 hour 
post-RIT-WBS were performed in all patients. How-
ever, this does not lead to misclassification of the other 
patients, since all patients were classified as stunning 
according to the definition in the literature. We did 
not perform quantitative analysis of the images to clas-
sify the cervical uptake in the post-RIT-WBS as posi-
tive, negative, or with reduction compared to dxWBS. 
These findings were undisputable. 
The lack of data of a control group (patients not 
receiving a dxWBS) and the impossibility to evaluate 
all the patients with 24-48 hours post-RIT-WBS appar-
ently did not interfere with the results obtained, and 
this argument may be corroborated by the fact that, 
in the current study, none of the 23 patients (11.1%) 
with progressive disease had thyroid stunning. Con-
versely, stunning occurred in 21.5% of patients without 
evidence of disease, and in 21.8% of patients with stable 
disease. In fact, stunning was also more likely to oc-
cur in younger patients and in those with nonaggressive 
variants, and this may also be related to better outcome. 
The patient population was also not heterogeneous as 
all patients were submitted to an initial dose for thyroid 
remnants and the majority (89%) solely to this initial 
dose for thyroid remnants. The remaining 11% were 
submitted to more doses because of metastatic disease 
that developed later during follow-up. 
Although many guidelines recommend 37 – 101 
MBq of iodine-131 dose for dxWBS in part due to 
stunning concerns, even with our dose of 185 MBq we 
did not find any difference of outcome among groups. 
Considering the use of 131I-iodide and its doses for 
dxWBS, this is exactly the protocol still used by many 
institutions and in recent studies, as described by Amin 
and cols. (23). The option for this protocol is based on 
the concern that the sensitivity in the detection of foci 
that present 131I-iodide uptake may be reduced, and 
the substitution for 123I-iodide, besides its high costs, 
is controversial, for this radiopharmaceutical treatment 
could increase the so-called stunning effect, due to the 
emission of Auger electrons by 123I-iodide (5). The 
stunning effect is not well-known, as also highlighted 
by the American Thyroid Association and the National 
Comprehensive Cancer Network (16), demanding new 
scientific studies with methodologies utilized in the 
routine clinical practice for better understanding of this 
phenomenon.
In conclusion, the occurrence of thyroid stunning 
did not reduce the efficiency of radioiodine therapy 
and did not impact negatively on patient outcomes in 
the group studied. Although all the limitations of the 
study, mainly the lack of control group and of a longer 
follow-up period, dxWBS may be performed safely and 
when necessary in DTC patients, and post-RIT-WBS 
after 24-48 hours, rather than after 10 days, should be 
considered. 
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